Remdesivir’s Approval for Covid Doesn't Erase Doubts, , on October 23, 2020 at 2:02 pm

Financial News
By
On October 23, 2020
In Financial News
Tags:

(Bloomberg Opinion) — Gilead Sciences Inc.’s remdesivir, now under the brand name Veklury, reached another milestone Thursday. It is now the first medicine to get full Food and Drug Administration approval to treat Covid-19. Investors seem to see the nod as a boost to the drug’s prospects, sending shares up more than 4% in early trading Friday after a recent slump. The agency’s decision isn’t likely to dramatically expand the use of the medicine, which has been available to patients through emergency use authorization since May. The data surrounding its modest benefit has become muddier, and it’s not clear why the FDA felt a more formal approval was needed, nor is it obvious that it should have granted one.Veklury’s full approval is based on three studies, the most important of which is a placebo-controlled trial run by the National Institutes of Health. It found that the drug sped recovery for patients by about five days but did not clearly reduce the risk of dying. But the FDA essentially ignored crucial new data about the medicine. A massive study from the World Health Organization released earlier this month found Veklury fails to prevent deaths or substantially improve outcomes. There are fair criticisms of the trial, which wasn’t double-blinded, gathered data from many different countries, and wasn’t designed to look directly at whether the drug speeds recovery. The FDA says it’s this last factor that led it to feel comfortable with its approval decision.The WHO study, though, was larger than the one the FDA focused on and looks at how Veklury is used in the real world. The lack of benefit adds to existing concerns about the drug’s true utility. It’s still unclear when the medicine is most useful or what patients it’s best suited to help. Medical experts aren’t just skeptical of Thursday’s decision; they had already registered concerns about the FDA’s August decision to expand the drug’s emergency use long before the WHO results. Formal approval will let Gilead promote the drug, which it couldn’t under its initial authorization. But it won’t erase those doubts, and rosy porjections of multibillion-dollar sales may be too optimistic.At the very least, the new results call Gilead’s $3,120 price tag into question. The Institute for Clinical and Economic Review, an independent drug pricing review group, said over the summer that a reasonable price for the drug was $2,520 to $2,800 per course when accounting for the availability of dexamethasone, a cheap steroid that does reduce the risk of death in severely ill Covid patients. With no mortality benefit, its assessment of a fair price for Veklury drops to $310. The FDA might have addressed some of these issues and built confidence in both the drug and its process if it had held a public meeting of experts to discuss full approval. It holds such panels routinely for other medicines and did so Thursday to discuss standards for Covid vaccines.Approval in that environment or with the backing of new and better data might have been grounds for real optimism. Instead, investors may be over-celebrating what looks like a rubber stamp.  This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.,

Remdesivir’s Approval for Covid Doesn't Erase Doubts(Bloomberg Opinion) — Gilead Sciences Inc.’s remdesivir, now under the brand name Veklury, reached another milestone Thursday. It is now the first medicine to get full Food and Drug Administration approval to treat Covid-19. Investors seem to see the nod as a boost to the drug’s prospects, sending shares up more than 4% in early trading Friday after a recent slump. The agency’s decision isn’t likely to dramatically expand the use of the medicine, which has been available to patients through emergency use authorization since May. The data surrounding its modest benefit has become muddier, and it’s not clear why the FDA felt a more formal approval was needed, nor is it obvious that it should have granted one.Veklury’s full approval is based on three studies, the most important of which is a placebo-controlled trial run by the National Institutes of Health. It found that the drug sped recovery for patients by about five days but did not clearly reduce the risk of dying. But the FDA essentially ignored crucial new data about the medicine. A massive study from the World Health Organization released earlier this month found Veklury fails to prevent deaths or substantially improve outcomes. There are fair criticisms of the trial, which wasn’t double-blinded, gathered data from many different countries, and wasn’t designed to look directly at whether the drug speeds recovery. The FDA says it’s this last factor that led it to feel comfortable with its approval decision.The WHO study, though, was larger than the one the FDA focused on and looks at how Veklury is used in the real world. The lack of benefit adds to existing concerns about the drug’s true utility. It’s still unclear when the medicine is most useful or what patients it’s best suited to help. Medical experts aren’t just skeptical of Thursday’s decision; they had already registered concerns about the FDA’s August decision to expand the drug’s emergency use long before the WHO results. Formal approval will let Gilead promote the drug, which it couldn’t under its initial authorization. But it won’t erase those doubts, and rosy porjections of multibillion-dollar sales may be too optimistic.At the very least, the new results call Gilead’s $3,120 price tag into question. The Institute for Clinical and Economic Review, an independent drug pricing review group, said over the summer that a reasonable price for the drug was $2,520 to $2,800 per course when accounting for the availability of dexamethasone, a cheap steroid that does reduce the risk of death in severely ill Covid patients. With no mortality benefit, its assessment of a fair price for Veklury drops to $310. The FDA might have addressed some of these issues and built confidence in both the drug and its process if it had held a public meeting of experts to discuss full approval. It holds such panels routinely for other medicines and did so Thursday to discuss standards for Covid vaccines.Approval in that environment or with the backing of new and better data might have been grounds for real optimism. Instead, investors may be over-celebrating what looks like a rubber stamp.  This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage